Research | Awards | More on Bernard P. Arulanandam
Bernard P. Arulanandam, Ph.D., M.B.A.
Professor of Microbiology & Immunology
Jane and Roland Blumberg Professorship in Biology
Assistant Vice President for Research Support
Associate Dean of Research for Scientific Innovation
College of Sciences, University of Texas at San Antonio
Director, San Antonio Vaccine Development Center
University of Texas San AntonioDepartment of Biology
Tel: (210) 458-5492Fax: (210) 458-5493Email:
University of Texas at San Antonio, San Antonio, TX. Executive M.B.A.
Medical College of Ohio, Toledo, OH. Ph.D., Microbiology & Immunology
Mucosal surfaces form the major interface between the host and the environment, and constitute the first line of defense against pathogens. The mammalian mucosal immune system has evolved into an intricate network of tissues, lymphoid and mucus membrane-associated cells and effector mechanisms for host protection. Our laboratory is focused on understanding the basic mechanism(s) of immune defenses at mucosal sites. The specific ongoing projects include the following:
Immunopathogenesis of Chlamydia trachomatis
There currently is no licensed vaccine against Chlamydia trachomatis, the leading cause of sexually transmitted bacterial disease worldwide. We are currently investigating various aspects of Chlamydia-induced pathogenesis utilizing genital and lung bacterial challenge models. The pathology produced by both genital (e.g., PID) and pulmonary infection of newborns (asthma-like consequences such as airway hyper-reactivity) result as a consequence of immunological sequeale to the primary or repeated infections with this pathogen.
Respiratory Defenses against Pulmonary Tularemia
Francisella tularensis is an intracellular Gram-negative bacterium that is the causative agent of tularemia. Inhalation of F. tularensis results in severe disease and a high fatality rate in humans. Our laboratory has recently shown the involvement of mast cells in early defenses against pulmonary tularemia. We are currently examining the mechanism(s) by which mast cells modulate innate immune defenses against this pathogen, and as a model for other Gram negative bacteria. Moreover, we are characterizing the use of defined F. tularensis mutants as live attenuated vaccine candidates against pneumonic tularemia.
Mucosal Defenses against Acinetobacter baumannii
Acinetobacter baumannii has emerged as an important nosocomial pathogen. There is evidence to suggest that gastrointestinal colonization of A. baumannii in humans precedes the onset of other clinical conditions such as septicemia, pneumonia and wound sepsis, with little known about the interaction of this pathogen with the gastrointestinal (GI) tract. We have developed an oral-gastrointestinal (GI) challenge model with A. baumannii to examine the contribution of mucosal immune defenses against gastrointestinal colonization by this pathogen and the subsequent systemic manifestation of this infection.
The Royal Society of Medicine
Scientific Research Society Sigma Xi
National Honor Society Phi Kappa Phi
International Cytokine Society
Society for Mucosal Immunology
American Association of Immunology
American Society of Microbiology
Chlamydia Basic Research Society
Open Vaccine Journal
Vaccine: Development and Therapy
Frontiers in Microbial Immunology-Review Editor
The following students are from the M&I Track:
[return to top]
This material is based upon the work supported by the Army Research Office of the Department of Defense under Contract No. W911NF-11-1-0136